 Emily Su
Concepts (215)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Placenta | 19 | 2024 | 714 | 5.500 |
Why?
| | Fetal Growth Retardation | 13 | 2024 | 544 | 4.770 |
Why?
| | Endothelial Cells | 10 | 2023 | 744 | 2.630 |
Why?
| | Estrogen Receptor beta | 6 | 2012 | 35 | 1.910 |
Why?
| | Umbilical Arteries | 3 | 2024 | 51 | 1.800 |
Why?
| | Neovascularization, Physiologic | 4 | 2021 | 181 | 1.660 |
Why?
| | Pregnancy | 33 | 2024 | 6301 | 1.370 |
Why?
| | Premature Birth | 6 | 2024 | 313 | 1.210 |
Why?
| | Hypertension, Pregnancy-Induced | 5 | 2024 | 67 | 1.180 |
Why?
| | Aryl Hydrocarbon Receptor Nuclear Translocator | 2 | 2019 | 17 | 1.130 |
Why?
| | Hypertension | 9 | 2024 | 1245 | 1.060 |
Why?
| | Antihypertensive Agents | 7 | 2024 | 489 | 1.050 |
Why?
| | Endometriosis | 6 | 2012 | 49 | 1.030 |
Why?
| | Chorionic Villi | 2 | 2024 | 22 | 0.930 |
Why?
| | Pregnancy Complications, Cardiovascular | 7 | 2024 | 80 | 0.920 |
Why?
| | Integrin alphaVbeta3 | 1 | 2022 | 20 | 0.820 |
Why?
| | Cell Movement | 4 | 2021 | 948 | 0.780 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 3 | 2022 | 70 | 0.740 |
Why?
| | Artificial Intelligence | 1 | 2024 | 251 | 0.710 |
Why?
| | Prostaglandins | 2 | 2011 | 85 | 0.680 |
Why?
| | Neovascularization, Pathologic | 2 | 2019 | 302 | 0.670 |
Why?
| | Pre-Eclampsia | 6 | 2024 | 183 | 0.660 |
Why?
| | Progesterone | 4 | 2010 | 244 | 0.640 |
Why?
| | Fetus | 5 | 2023 | 768 | 0.640 |
Why?
| | Uveomeningoencephalitic Syndrome | 1 | 2019 | 7 | 0.630 |
Why?
| | Estrogens | 2 | 2012 | 355 | 0.630 |
Why?
| | 17-Hydroxysteroid Dehydrogenases | 2 | 2010 | 5 | 0.620 |
Why?
| | Panuveitis | 1 | 2019 | 7 | 0.620 |
Why?
| | Adalimumab | 1 | 2019 | 45 | 0.620 |
Why?
| | Female | 44 | 2024 | 68842 | 0.580 |
Why?
| | Pregnancy Outcome | 7 | 2024 | 381 | 0.560 |
Why?
| | Extracellular Matrix | 1 | 2021 | 500 | 0.550 |
Why?
| | Benzo(a)pyrene | 1 | 2016 | 7 | 0.530 |
Why?
| | Cyclooxygenase 2 | 3 | 2016 | 176 | 0.510 |
Why?
| | Vascular Endothelial Growth Factor A | 6 | 2022 | 533 | 0.510 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2016 | 52 | 0.510 |
Why?
| | Endothelium, Vascular | 5 | 2018 | 926 | 0.500 |
Why?
| | Signal Transduction | 5 | 2019 | 4930 | 0.470 |
Why?
| | Endometrium | 4 | 2012 | 61 | 0.440 |
Why?
| | Reproduction | 2 | 2012 | 201 | 0.420 |
Why?
| | Stillbirth | 1 | 2013 | 59 | 0.410 |
Why?
| | Umbilical Cord | 1 | 2013 | 84 | 0.410 |
Why?
| | Cell Proliferation | 2 | 2018 | 2381 | 0.410 |
Why?
| | Humans | 44 | 2024 | 130305 | 0.410 |
Why?
| | Fetal Diseases | 1 | 2013 | 148 | 0.390 |
Why?
| | Endothelium | 1 | 2011 | 116 | 0.360 |
Why?
| | Infant, Newborn | 12 | 2024 | 5741 | 0.340 |
Why?
| | Ultrasonography, Doppler | 2 | 2024 | 119 | 0.330 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2007 | 290 | 0.320 |
Why?
| | Women's Health | 1 | 2012 | 362 | 0.310 |
Why?
| | Birth Weight | 3 | 2024 | 499 | 0.310 |
Why?
| | Estradiol | 3 | 2011 | 498 | 0.310 |
Why?
| | Promegestone | 1 | 2007 | 33 | 0.280 |
Why?
| | Postpartum Period | 3 | 2024 | 332 | 0.280 |
Why?
| | Adult | 16 | 2024 | 35711 | 0.260 |
Why?
| | Estrogen Receptor alpha | 3 | 2012 | 135 | 0.250 |
Why?
| | Up-Regulation | 3 | 2019 | 856 | 0.250 |
Why?
| | Fetal Development | 2 | 2023 | 283 | 0.250 |
Why?
| | Placental Circulation | 2 | 2017 | 63 | 0.230 |
Why?
| | Labetalol | 1 | 2024 | 7 | 0.230 |
Why?
| | Case-Control Studies | 4 | 2021 | 3369 | 0.230 |
Why?
| | Nifedipine | 1 | 2024 | 28 | 0.230 |
Why?
| | Uterus | 2 | 2017 | 205 | 0.220 |
Why?
| | Delivery, Obstetric | 1 | 2024 | 135 | 0.210 |
Why?
| | Gestational Age | 5 | 2024 | 868 | 0.210 |
Why?
| | Cannabidiol | 1 | 2024 | 90 | 0.210 |
Why?
| | Breast Feeding | 2 | 2024 | 427 | 0.210 |
Why?
| | Integrin alpha5beta1 | 1 | 2022 | 11 | 0.200 |
Why?
| | Regional Blood Flow | 2 | 2017 | 463 | 0.200 |
Why?
| | Dronabinol | 1 | 2024 | 167 | 0.200 |
Why?
| | Pregnancy in Diabetics | 1 | 2024 | 119 | 0.200 |
Why?
| | Cells, Cultured | 5 | 2021 | 4106 | 0.200 |
Why?
| | Epoprostenol | 2 | 2016 | 136 | 0.200 |
Why?
| | Extracellular Matrix Proteins | 1 | 2023 | 146 | 0.200 |
Why?
| | Chronic Disease | 6 | 2024 | 1727 | 0.200 |
Why?
| | Stromal Cells | 3 | 2012 | 107 | 0.200 |
Why?
| | Fibronectins | 1 | 2022 | 119 | 0.190 |
Why?
| | Trophoblasts | 2 | 2021 | 189 | 0.190 |
Why?
| | Furin | 1 | 2021 | 13 | 0.180 |
Why?
| | Receptors, Virus | 1 | 2021 | 83 | 0.180 |
Why?
| | Steroidogenic Factor 1 | 2 | 2012 | 6 | 0.180 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 79 | 0.180 |
Why?
| | Serine Endopeptidases | 1 | 2021 | 117 | 0.170 |
Why?
| | Receptors, Progesterone | 3 | 2012 | 345 | 0.170 |
Why?
| | Cohort Studies | 4 | 2024 | 5431 | 0.170 |
Why?
| | Models, Biological | 2 | 2017 | 1716 | 0.160 |
Why?
| | RNA Interference | 3 | 2011 | 453 | 0.160 |
Why?
| | Triamcinolone | 1 | 2019 | 15 | 0.160 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2018 | 86 | 0.150 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2024 | 553 | 0.150 |
Why?
| | Mycophenolic Acid | 1 | 2019 | 100 | 0.150 |
Why?
| | Remission Induction | 1 | 2019 | 270 | 0.150 |
Why?
| | Hypertension, Pulmonary | 2 | 2022 | 1890 | 0.150 |
Why?
| | Fluorescein Angiography | 1 | 2019 | 144 | 0.150 |
Why?
| | Headache | 1 | 2019 | 139 | 0.140 |
Why?
| | Gene Expression Regulation | 3 | 2012 | 2549 | 0.140 |
Why?
| | Fetal Blood | 2 | 2017 | 316 | 0.140 |
Why?
| | Tomography, Optical Coherence | 1 | 2019 | 187 | 0.140 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 962 | 0.140 |
Why?
| | Research Design | 1 | 2023 | 1052 | 0.140 |
Why?
| | Visual Acuity | 1 | 2019 | 323 | 0.130 |
Why?
| | Lab-On-A-Chip Devices | 1 | 2016 | 35 | 0.130 |
Why?
| | Epigenesis, Genetic | 2 | 2012 | 620 | 0.130 |
Why?
| | Drug Therapy, Combination | 1 | 2019 | 1028 | 0.130 |
Why?
| | Cesarean Section | 3 | 2024 | 182 | 0.120 |
Why?
| | Maternal-Fetal Exchange | 1 | 2016 | 161 | 0.120 |
Why?
| | Blood Flow Velocity | 1 | 2015 | 413 | 0.110 |
Why?
| | Abruptio Placentae | 2 | 2024 | 5 | 0.110 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2019 | 1210 | 0.110 |
Why?
| | Growth Disorders | 1 | 2014 | 78 | 0.110 |
Why?
| | Infant, Premature | 2 | 2017 | 542 | 0.110 |
Why?
| | Vascular Resistance | 1 | 2015 | 373 | 0.110 |
Why?
| | Blood Pressure | 3 | 2024 | 1753 | 0.100 |
Why?
| | Fetal Distress | 1 | 2012 | 12 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2010 | 1341 | 0.100 |
Why?
| | Ovarian Diseases | 1 | 2012 | 12 | 0.100 |
Why?
| | Oogenesis | 1 | 2012 | 24 | 0.100 |
Why?
| | Ovulation | 1 | 2012 | 40 | 0.100 |
Why?
| | Eicosanoids | 1 | 2012 | 56 | 0.100 |
Why?
| | Chorioamnionitis | 1 | 2012 | 38 | 0.100 |
Why?
| | Placentation | 1 | 2012 | 44 | 0.100 |
Why?
| | Estrogen Antagonists | 1 | 2012 | 45 | 0.100 |
Why?
| | Pregnancy Proteins | 1 | 2012 | 37 | 0.100 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2017 | 383 | 0.090 |
Why?
| | Muscle Tonus | 1 | 2011 | 19 | 0.090 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2011 | 73 | 0.090 |
Why?
| | Parturition | 1 | 2012 | 67 | 0.090 |
Why?
| | Metabolic Networks and Pathways | 1 | 2012 | 176 | 0.090 |
Why?
| | Ultrasonography | 1 | 2015 | 731 | 0.090 |
Why?
| | Large Neutral Amino Acid-Transporter 1 | 1 | 2010 | 15 | 0.090 |
Why?
| | Prospective Studies | 4 | 2024 | 7131 | 0.090 |
Why?
| | Vasoconstriction | 1 | 2011 | 195 | 0.090 |
Why?
| | Placenta Growth Factor | 2 | 2022 | 23 | 0.080 |
Why?
| | Myometrium | 1 | 2010 | 36 | 0.080 |
Why?
| | Leiomyoma | 1 | 2010 | 73 | 0.080 |
Why?
| | Paracrine Communication | 1 | 2010 | 62 | 0.080 |
Why?
| | Thromboxanes | 1 | 2009 | 16 | 0.080 |
Why?
| | Apoptosis | 1 | 2018 | 2519 | 0.080 |
Why?
| | Uterine Neoplasms | 1 | 2010 | 101 | 0.080 |
Why?
| | Retrospective Studies | 2 | 2024 | 14675 | 0.080 |
Why?
| | Molecular Targeted Therapy | 1 | 2012 | 389 | 0.080 |
Why?
| | Blotting, Western | 1 | 2011 | 1201 | 0.080 |
Why?
| | Neoplasm Proteins | 1 | 2012 | 430 | 0.080 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2010 | 255 | 0.070 |
Why?
| | Vasodilation | 1 | 2011 | 481 | 0.070 |
Why?
| | Retinoid X Receptor alpha | 1 | 2007 | 4 | 0.070 |
Why?
| | Progesterone Congeners | 1 | 2007 | 16 | 0.070 |
Why?
| | Glucocorticoids | 1 | 2012 | 583 | 0.070 |
Why?
| | Retinoic Acid Receptor alpha | 1 | 2007 | 11 | 0.070 |
Why?
| | Breast Neoplasms | 2 | 2012 | 2139 | 0.070 |
Why?
| | Aromatase | 1 | 2007 | 31 | 0.070 |
Why?
| | Promoter Regions, Genetic | 1 | 2012 | 1207 | 0.070 |
Why?
| | Receptors, Retinoic Acid | 1 | 2007 | 51 | 0.070 |
Why?
| | Immunohistochemistry | 1 | 2011 | 1711 | 0.070 |
Why?
| | Immunoblotting | 1 | 2007 | 304 | 0.070 |
Why?
| | Fluorescent Antibody Technique | 1 | 2007 | 393 | 0.070 |
Why?
| | Animals | 4 | 2012 | 35076 | 0.060 |
Why?
| | Databases, Factual | 1 | 2011 | 1300 | 0.060 |
Why?
| | Endometrial Neoplasms | 1 | 2007 | 163 | 0.060 |
Why?
| | Infant, Small for Gestational Age | 1 | 2024 | 84 | 0.050 |
Why?
| | RNA, Messenger | 2 | 2010 | 2732 | 0.050 |
Why?
| | Arterial Pressure | 1 | 2024 | 118 | 0.050 |
Why?
| | Biomarkers | 3 | 2022 | 3923 | 0.050 |
Why?
| | Triage | 1 | 2024 | 214 | 0.050 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2022 | 77 | 0.050 |
Why?
| | Cell Differentiation | 1 | 2010 | 1896 | 0.050 |
Why?
| | Administration, Oral | 1 | 2024 | 788 | 0.050 |
Why?
| | Ovarian Neoplasms | 1 | 2007 | 488 | 0.050 |
Why?
| | Fetal Hypoxia | 1 | 2022 | 51 | 0.050 |
Why?
| | Virus Internalization | 1 | 2021 | 46 | 0.050 |
Why?
| | Child Development | 1 | 2024 | 454 | 0.040 |
Why?
| | Child | 1 | 2019 | 20961 | 0.040 |
Why?
| | Patient Acceptance of Health Care | 1 | 2024 | 771 | 0.040 |
Why?
| | Altitude | 1 | 2022 | 451 | 0.040 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2021 | 336 | 0.030 |
Why?
| | Middle Aged | 3 | 2013 | 31322 | 0.030 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2017 | 72 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2022 | 1974 | 0.030 |
Why?
| | Male | 4 | 2024 | 63748 | 0.030 |
Why?
| | Microvilli | 1 | 2016 | 77 | 0.030 |
Why?
| | Proof of Concept Study | 1 | 2016 | 64 | 0.030 |
Why?
| | Infant, Extremely Premature | 1 | 2017 | 60 | 0.030 |
Why?
| | Body Mass Index | 1 | 2024 | 2268 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2016 | 226 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2016 | 309 | 0.030 |
Why?
| | Hospitalization | 1 | 2024 | 2094 | 0.030 |
Why?
| | Equipment Design | 1 | 2016 | 526 | 0.030 |
Why?
| | Adolescent | 1 | 2013 | 20374 | 0.030 |
Why?
| | Proteomics | 1 | 2020 | 1008 | 0.030 |
Why?
| | Time Factors | 1 | 2024 | 6615 | 0.030 |
Why?
| | Emergency Service, Hospital | 1 | 2024 | 1986 | 0.030 |
Why?
| | Young Adult | 2 | 2024 | 12404 | 0.030 |
Why?
| | Mice | 1 | 2010 | 16832 | 0.030 |
Why?
| | Cardiotocography | 1 | 2012 | 3 | 0.030 |
Why?
| | Fetal Monitoring | 1 | 2012 | 15 | 0.030 |
Why?
| | Heart Rate, Fetal | 1 | 2012 | 20 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2012 | 123 | 0.020 |
Why?
| | Infant | 1 | 2024 | 9049 | 0.020 |
Why?
| | Cell Line | 1 | 2016 | 2786 | 0.020 |
Why?
| | Hormone Antagonists | 1 | 2010 | 30 | 0.020 |
Why?
| | Mifepristone | 1 | 2010 | 63 | 0.020 |
Why?
| | Child, Preschool | 1 | 2024 | 10514 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2024 | 10341 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2691 | 0.020 |
Why?
| | CpG Islands | 1 | 2010 | 152 | 0.020 |
Why?
| | Acute Disease | 1 | 2012 | 981 | 0.020 |
Why?
| | Dinoprostone | 1 | 2008 | 189 | 0.020 |
Why?
| | Cell Survival | 1 | 2010 | 1098 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2010 | 1983 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2012 | 1714 | 0.010 |
Why?
| | DNA Methylation | 1 | 2010 | 610 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2012 | 2785 | 0.010 |
Why?
| | United States | 1 | 2020 | 14110 | 0.010 |
Why?
| | Transcription Factors | 1 | 2008 | 1649 | 0.010 |
Why?
| | Inflammation | 1 | 2008 | 2721 | 0.010 |
Why?
|
|
Su's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|